ATE297984T1 - Mit hiv-2 infizierte menschliche t-zelllinie die funktionell intaktes hiv-2 gp160 sekretiert - Google Patents

Mit hiv-2 infizierte menschliche t-zelllinie die funktionell intaktes hiv-2 gp160 sekretiert

Info

Publication number
ATE297984T1
ATE297984T1 AT96200578T AT96200578T ATE297984T1 AT E297984 T1 ATE297984 T1 AT E297984T1 AT 96200578 T AT96200578 T AT 96200578T AT 96200578 T AT96200578 T AT 96200578T AT E297984 T1 ATE297984 T1 AT E297984T1
Authority
AT
Austria
Prior art keywords
hiv
cell line
protein
humans
purified
Prior art date
Application number
AT96200578T
Other languages
English (en)
Inventor
Mangalasseril Gop Sarngadharan
Vaniambadi Sriniv Kalyanaraman
Kalisz Irene Larue
Original Assignee
Bio Merieux Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Merieux Inc filed Critical Bio Merieux Inc
Application granted granted Critical
Publication of ATE297984T1 publication Critical patent/ATE297984T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/162—HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
AT96200578T 1995-03-07 1996-03-04 Mit hiv-2 infizierte menschliche t-zelllinie die funktionell intaktes hiv-2 gp160 sekretiert ATE297984T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/402,481 US5736317A (en) 1995-03-07 1995-03-07 Human T-cell line infected with HIV-2 which secretes a protein corresponding to native HIV-2 gp160 in an extracellular medium

Publications (1)

Publication Number Publication Date
ATE297984T1 true ATE297984T1 (de) 2005-07-15

Family

ID=23592081

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96200578T ATE297984T1 (de) 1995-03-07 1996-03-04 Mit hiv-2 infizierte menschliche t-zelllinie die funktionell intaktes hiv-2 gp160 sekretiert

Country Status (10)

Country Link
US (3) US5736317A (de)
EP (1) EP0731165B8 (de)
JP (1) JPH09246A (de)
KR (1) KR960034405A (de)
AT (1) ATE297984T1 (de)
AU (1) AU710064B2 (de)
CA (1) CA2171144A1 (de)
DE (1) DE69634843T2 (de)
ES (1) ES2240986T3 (de)
ZA (1) ZA961647B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208321A (en) 1988-06-09 1993-05-04 Institut Pasteur HIV-2 transmembrane glycoprotein homodimer (GP 80)
US6197496B1 (en) 1988-06-09 2001-03-06 Institut Pasteur Immunological reagents and diagnostic methods for the detection of human immunodeficiency virus type 2 utilizing multimeric forms of the envelope proteins gp300, p200, and p90/80
US6271077B1 (en) 1995-03-27 2001-08-07 Fujitsu Limited Thin film deposition method, capacitor device and method for fabricating the same, and semiconductor device and method for fabricating the same
US6410692B2 (en) * 1998-02-02 2002-06-25 Novadx, Inc. Removal of abundant interfering proteins from a liquid sample using a collapsible affinity matrix
JP2004512262A (ja) 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
EP2277897A1 (de) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Polypeptideantigene codierende offene Leseraster aus Streptococcus pneumoniae und Verwendungen davon
CN1500806B (zh) * 2002-11-14 2010-05-05 上海科华生物工程股份有限公司 一种HIV－1ɡp160膜蛋白及其制备方法和应用
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
WO2007095336A2 (en) * 2006-02-15 2007-08-23 The Immune Response Corporation Production of hiv
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3712334C2 (de) * 1987-04-11 1995-04-27 Paul Ehrlich Inst Bundesamt Fu Verfahren zum Züchten von HIV-2-Viren, dazu geeignete Zellkulturen sowie diagnostische Mittel zum Nachweis von HIV-2-Viren und Verfahren zu ihrer Herstellung
WO1989006276A2 (en) * 1988-01-08 1989-07-13 Dpz Deutsches Primatenzentrum Gesellschaft Mbh Hiv-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions
US5122468A (en) * 1988-08-16 1992-06-16 Akzo N.V. Hut-78 cell lines infected with HTLV-III which secrete gp160
US5116740A (en) * 1988-08-16 1992-05-26 Akzo N.V. Method for producing native hiv gp160

Also Published As

Publication number Publication date
DE69634843D1 (de) 2005-07-21
EP0731165A2 (de) 1996-09-11
EP0731165A3 (de) 1999-09-08
AU4792996A (en) 1996-09-19
JPH09246A (ja) 1997-01-07
US5736317A (en) 1998-04-07
CA2171144A1 (en) 1996-09-08
DE69634843T2 (de) 2006-05-04
US5766844A (en) 1998-06-16
EP0731165B1 (de) 2005-06-15
ZA961647B (en) 1996-09-05
US5876732A (en) 1999-03-02
ES2240986T3 (es) 2005-10-16
EP0731165B8 (de) 2005-08-10
AU710064B2 (en) 1999-09-09
KR960034405A (ko) 1996-10-22

Similar Documents

Publication Publication Date Title
ATE297984T1 (de) Mit hiv-2 infizierte menschliche t-zelllinie die funktionell intaktes hiv-2 gp160 sekretiert
EP0196319B1 (de) Retrovirale polypeptide in zusammenhang mit menschlicher transformation
EP0327801A1 (de) HIV-2-Typ-Retrovirus von Primaten, Vakzine sowie diagnostische und pharmazeutische Zusammensetzungen
US5550052A (en) Hybrid cell line formed between T4 lymphocytes and tumoral lymphoid type cells
Berger et al. Demonstration of IgA polioantibody in saliva, duodenal fluid and urine
DE69334148D1 (de) HIV-Peptide
DE69131513D1 (de) Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon
JPH02160800A (ja) ヒト免疫不全ウイルス（ＨＩＶ）ｅｎｖ‐コードペプチド
US5364933A (en) Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2)
US5374518A (en) Monoclonal antibody for differentiating HIV-2 from HIM-1 seropositive individuals
EP0211022A1 (de) Monoklonale antikörper gegen kernproteine von lymphadenopathie-assoziierten viren.
US6531574B1 (en) T-lymphotrophic virus
Chassagne et al. A monoclonal antibody against LAV gag precursor: use for viral protein analysis and antigenic expression in infected cells.
Tozawa et al. Species‐dependent antigenicity of the 34‐kDa glycoprotein found on the membrane of various primate lymphocytes transformed by human t‐cell leukemia virus type‐I (HTLV‐I) and simian T‐cell leukemia virus (STLV‐I)
CA1339363C (en) Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
US5116740A (en) Method for producing native hiv gp160
DE3850593T2 (de) Synthetische Antigene zur Bestimmung der AIDS-bezogenen, von LAV-2 verursachten Krankheiten.
Lasfargues et al. In vitro susceptibility of mink lung cells to the mouse mammary tumor virus
US6165710A (en) Method for immobilizing viral glycoproteins for use in solid-phase immunoassays
AU614543B2 (en) Hiv-1-related polypeptides, diagnostic systems and assay methods
US5122468A (en) Hut-78 cell lines infected with HTLV-III which secrete gp160
Scott et al. Monoclonal antibodies produced to bean yellow mosaic virus, clover yellow vein virus, and pea mosaic virus which cross-react among the three viruses
Prigent et al. Production and characterization of human monoclonal antibodies against core protein p25 and transmembrane glycoprotein gp41 of HIV-1
Kusk et al. Immunological characterization and detection of the major core protein p24 of the human immunodeficiency virus (HIV) using monoclonal antibodies
KR0166344B1 (ko) 사람 면역결핍 바이러스 타입 1의 항원단백질 p24를 제조하는 방법

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties